• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Change in Platelet Count after Transjugular Intrahepatic Portosystemic Shunt Creation: An Advancing Liver Therapeutic Approaches (ALTA) Group Study.经颈静脉肝内门体分流术(TIPS)创建后血小板计数的变化:肝脏治疗方法(ALTA)研究组的研究。
J Vasc Interv Radiol. 2023 Aug;34(8):1364-1371. doi: 10.1016/j.jvir.2023.04.015. Epub 2023 Apr 24.
2
Early Liver Failure after Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis with Model for End-Stage Liver Disease Score of 12 or Less: Incidence, Outcome, and Prognostic Factors.肝硬化患者经颈静脉肝内门体分流术(TIPS)后早期肝衰竭:发生率、结局和预后因素,模型终末期肝病评分(MELD)为 12 分或以下。
Radiology. 2016 Aug;280(2):622-9. doi: 10.1148/radiol.2016151625. Epub 2016 Mar 14.
3
Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.社会经济地位与经颈静脉肝内门体分流术创建后肝性脑病的风险相关。
J Vasc Interv Radiol. 2021 Jul;32(7):950-960.e1. doi: 10.1016/j.jvir.2020.11.022. Epub 2021 Mar 2.
4
MELD 3.0 Score for Predicting Survival in Patients with Cirrhosis After Transjugular Intrahepatic Portosystemic Shunt Creation.MELD3.0 评分预测经颈静脉肝内门体分流术创建后肝硬化患者的生存。
Dig Dis Sci. 2023 Jul;68(7):3185-3192. doi: 10.1007/s10620-023-07834-3. Epub 2023 Jan 30.
5
Psoas Muscle Density in Combination with Model for End-Stage Liver Disease Score Can Improve Survival Predictability in Transjugular Intrahepatic Portosystemic Shunts.腰大肌密度联合终末期肝病模型评分可提高经颈静脉肝内门体分流术的生存预测能力。
J Vasc Interv Radiol. 2019 Feb;30(2):154-161. doi: 10.1016/j.jvir.2018.10.006.
6
Different scoring systems in predicting survival in Chinese patients with liver cirrhosis undergoing transjugular intrahepatic portosystemic shunt.不同评分系统对接受经颈静脉肝内门体分流术的中国肝硬化患者生存情况的预测
Eur J Gastroenterol Hepatol. 2014 Aug;26(8):853-60. doi: 10.1097/MEG.0000000000000134.
7
Coated transjugular intrahepatic portosystemic shunt does not improve thrombocytopenia in patients with liver cirrhosis.覆膜经颈静脉肝内门体分流术不能改善肝硬化患者的血小板减少症。
Dig Dis Sci. 2012 Sep;57(9):2430-7. doi: 10.1007/s10620-012-2162-z. Epub 2012 May 16.
8
Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.经颈静脉肝内门体分流术后肝性脑病预测的吲哚菁绿-R15、Child-Pugh 评分和终末期肝病模型评分的对比研究。
World J Gastroenterol. 2021 Feb 7;27(5):416-427. doi: 10.3748/wjg.v27.i5.416.
9
The impact of thrombocytopenia on variceal bleeding in cirrhotic patients with transjugular intrahepatic portosystemic shunt.经颈静脉肝内门体分流术治疗的肝硬化患者血小板减少症对静脉曲张出血的影响。
Sci Rep. 2023 Jan 30;13(1):1633. doi: 10.1038/s41598-023-28646-5.
10
Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis.肝硬化患者经颈静脉肝内门体分流术(TIPS)后门静脉高压性脑病的危险因素。
J Dig Dis. 2021 Jan;22(1):31-40. doi: 10.1111/1751-2980.12957. Epub 2020 Nov 26.

本文引用的文献

1
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.慢性肝脏疾病中的血小板减少症:侵入性操作前的病理生理学和新的治疗策略。
World J Gastroenterol. 2022 Aug 14;28(30):4061-4074. doi: 10.3748/wjg.v28.i30.4061.
2
Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study.经 TIPS 治疗腹水和静脉曲张出血的结果:当代 ALTA 研究组研究。
Am J Gastroenterol. 2021 Oct 1;116(10):2079-2088. doi: 10.14309/ajg.0000000000001357.
3
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.肝病患者的血管性肝脏疾病、门静脉血栓形成及操作出血:美国肝病研究协会2020年实践指南
Hepatology. 2021 Jan;73(1):366-413. doi: 10.1002/hep.31646. Epub 2021 Jan 20.
4
Nonalcoholic Fatty Liver Disease and Diabetes Mellitus Are Associated With Post-Transjugular Intrahepatic Portosystemic Shunt Renal Dysfunction: An Advancing Liver Therapeutic Approaches Group Study.非酒精性脂肪性肝病和糖尿病与经颈静脉肝内门体分流术后肾功能障碍相关:肝脏治疗方法进展组的一项研究。
Liver Transpl. 2021 Feb;27(3):329-340. doi: 10.1002/lt.25949. Epub 2021 Jan 2.
5
Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options.肝硬化中的血小板减少症:病理生理学与管理选择综述
Clin Liver Dis (Hoboken). 2019 Dec 20;14(5):183-186. doi: 10.1002/cld.860. eCollection 2019 Nov.
6
The Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis.经颈静脉肝内门体分流术对肝硬化患者血小板计数的影响
Gastroenterol Hepatol (N Y). 2017 May;13(5):286-291.
7
Thrombocytopenia in chronic liver disease.慢性肝病中的血小板减少症。
Liver Int. 2017 Jun;37(6):778-793. doi: 10.1111/liv.13317. Epub 2016 Dec 27.
8
Platelet function and ageing.血小板功能与衰老
Mamm Genome. 2016 Aug;27(7-8):358-66. doi: 10.1007/s00335-016-9629-8. Epub 2016 Apr 11.
9
Management of thrombocytopenia in advanced liver disease.晚期肝病血小板减少症的管理。
Can J Gastroenterol Hepatol. 2014 Nov;28(10):558-64. doi: 10.1155/2014/532191. Epub 2014 Sep 15.
10
How quickly does ascites respond to TIPS? Clinical follow-up of a cohort of eighty patients.腹水对经颈静脉肝内门体分流术(TIPS)的反应有多快?对80例患者队列的临床随访
Diagn Interv Radiol. 2014 Jul-Aug;20(4):364. doi: 10.5152/dir.2014.13479.

经颈静脉肝内门体分流术(TIPS)创建后血小板计数的变化:肝脏治疗方法(ALTA)研究组的研究。

Change in Platelet Count after Transjugular Intrahepatic Portosystemic Shunt Creation: An Advancing Liver Therapeutic Approaches (ALTA) Group Study.

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of California San Francisco, San Francisco, California.

Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

出版信息

J Vasc Interv Radiol. 2023 Aug;34(8):1364-1371. doi: 10.1016/j.jvir.2023.04.015. Epub 2023 Apr 24.

DOI:10.1016/j.jvir.2023.04.015
PMID:37100199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10998695/
Abstract

PURPOSE

To evaluate recovery of platelet count after transjugular intrahepatic portosystemic shunt (TIPS) creation and patient factors predicting platelet recovery after TIPS creation.

MATERIALS AND METHODS

Adults with cirrhosis who underwent TIPS creation at 9 U.S. hospitals from 2010 to 2015 were included in this retrospective analysis. Change in platelets from before TIPS to 4 months after TIPS creation was characterized. Logistic regression was used to assess factors associated with top quartile percentage platelet increase after TIPS. Subgroup analyses were performed among patients with a pre-TIPS platelet count of ≤50 ×10/L.

RESULTS

A total of 601 patients were included. The median absolute change in platelets was 1 × 10/L (-26 × 10/L to 25 × 10/L). Patients with top quartile percent platelet increase experienced ≥32% platelet increase. In multivariable analysis, pre-TIPS platelet counts (odds ratio [OR], 0.97 per 10/L; 95% CI, 0.97-0.98), age (OR, 1.24 per 5 years; 95% CI, 1.10-1.39), and pre-TIPS model for end-stage liver disease (MELD) scores (OR, 1.06 per point; 95% CI, 1.02-1.09) were associated with top quartile (≥32%) platelet increase. Ninety-four (16%) patients had a platelet count of ≤50 × 10/L before TIPS. The median absolute platelet change was 14 × 10/L (2 × 10/L to 34 × 10/L). Fifty-four percent of patients in this subgroup were in the top quartile for platelet increase. In multivariable logistic regression, age (OR, 1.50 per 5 years; 95% CI, 1.11-2.02) was the only factor associated with top quartile platelet increase in this subgroup.

CONCLUSIONS

TIPS creation did not result in significant platelet increase, except among patients with a platelet count of ≤50 × 10/L before TIPS. Lower pre-TIPS platelet counts, older age, and higher pre-TIPS MELD scores were associated with top quartile (≥32%) platelet increase in the entire cohort, whereas only older age was associated with this outcome in the patient subset with a pre-TIPS platelet count of ≤50 × 10/L.

摘要

目的

评估经颈静脉肝内门体分流术(TIPS)创建后血小板计数的恢复情况,以及预测 TIPS 创建后血小板恢复的患者因素。

材料与方法

本回顾性分析纳入了 2010 年至 2015 年在美国 9 家医院接受 TIPS 治疗的肝硬化成人患者。分析 TIPS 治疗前至治疗后 4 个月血小板的变化。采用 logistic 回归评估 TIPS 后血小板百分比增加最高四分位的相关因素。在血小板计数治疗前≤50×10/L 的患者中进行亚组分析。

结果

共纳入 601 例患者。血小板绝对值平均变化为 1×10/L(-26×10/L 至 25×10/L)。血小板百分比增加最高四分位的患者血小板增加≥32%。多变量分析显示,TIPS 治疗前血小板计数(比值比[OR],每 10/L 增加 0.97;95%置信区间[CI],0.97-0.98)、年龄(OR,每 5 岁增加 1.24;95%CI,1.10-1.39)和 TIPS 治疗前终末期肝病模型(MELD)评分(OR,每增加 1 分增加 1.06;95%CI,1.02-1.09)与血小板增加最高四分位(≥32%)相关。94 例(16%)患者 TIPS 治疗前血小板计数≤50×10/L。血小板绝对值平均变化为 14×10/L(2×10/L 至 34×10/L)。该亚组中 54%的患者血小板增加处于最高四分位。在多变量逻辑回归中,年龄(OR,每 5 岁增加 1.50;95%CI,1.11-2.02)是该亚组中唯一与血小板增加最高四分位相关的因素。

结论

TIPS 治疗并未导致明显的血小板增加,除了治疗前血小板计数≤50×10/L 的患者。在整个队列中,较低的 TIPS 治疗前血小板计数、较大的年龄和较高的 TIPS 治疗前 MELD 评分与血小板增加最高四分位(≥32%)相关,而在 TIPS 治疗前血小板计数≤50×10/L 的患者亚组中,仅年龄与这一结果相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/a055da612d5d/nihms-1981983-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/9fd0689b1b13/nihms-1981983-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/b620ed069aa2/nihms-1981983-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/a055da612d5d/nihms-1981983-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/9fd0689b1b13/nihms-1981983-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/b620ed069aa2/nihms-1981983-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4ac/10998695/a055da612d5d/nihms-1981983-f0003.jpg